Monitoring clinical trials of therapeutic vaccines in HIV infection: Role of treatment interruption

Current Opinion in HIV and AIDS

Volumn 2, Issue 1, 2007, Pages 56-61

  Lederman, Michael M ^a   Penn Nicholson, Adam ^a   Stone, Shelley F ^a   Sieg, Scott F ^a   Rodriguez, Benigno ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytotoxic T lymphocytes; Therapeutic vaccine; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; CHICKENPOX VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RABIES VACCINE;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW; VACCINATION; VIREMIA; VIRUS REPLICATION;

EID: 34250633199     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3280119264     Document Type: Review

References (52)

1. Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13:1873-1880.
2. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19:463-471.
3. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-814. After a sustained (greater than 48-week) period of virological control, the simplification of HAART regimens to boosted atazanvir alone permitted 24 weeks of virological control without rebound in 31 out of 34 patients. The simplification of antiviral therapies may thus be possible in some settings.
4. Anonymous. Centers for Disease Control and Prevention. Human rabies prevention - United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999; 48:1-21.
5. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2:1099-1102.
6. Anderson LJ, Nicholson KG, Tauxe RV, Winkler WG. Human rabies in the United States, 1960 to 1979: epidemiology, diagnosis, and prevention. Ann Intern Med 1984; 100:728-735.
7. Robinson WS, Hepatitis B virus and hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, ed. 5, vol. II. New York. Churchill Livingstone 2000. pp. 1652-1684.
8. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-2284. This landmark study is the first to demonstrate the clinical utility of a therapeutic vaccine strategy in individuals with a chronic established viral infection.
9. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-98.
10. Harari A, Cellerai C, Pantaleo G. Role of HIV-1 specific CD4 cells. Curr Opin HIV AIDS 2006; 1:22-27.
11. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994; 68:8056-8063.
12. Lieberman J, Shankar P, Manjunath N, Andersson J. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001; 98:1667-1677.
13. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8(+) T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068.
14. Sieg S, Mitchem JB, Bazdar D, Lederman MM. CD4+ and CD8+ T cell proliferation failure are tightly linked in HIV disease and are related to extended periods of CD4 lymphopenia. J Infect Dis 2002; 185:1401-1416.
15. Sieg SF, Bazdar DA, Lederman MM. Impaired TCR-mediated induction of Ki67 by naive CD4+ T cells is only occasionally corrected by exogenous IL-2 in HIV-1 infection. J Immunol 2003; 171:5208-5214.
16. Sieg SF, Harding CV, Lederman MM. HIV-1 infection impairs cell cycle progression of CD4(+) T cells without affecting early activation responses. J Clin Invest 2001; 108:757-764.
17. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
18. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-492.
19. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-339.
20. Eron JJ Jr, Ashby MA, Giordano MF, et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996; 348:1547-1551.
21. Kahn JO, Cherng DW, Mayer K, et al. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: a randomized controlled trial. JAMA 2000; 284:2193-2202.
22. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med 1991; 324:1677-1684.
23. Schooley RT, Spino C, Kuritzkes D, et al. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis 2000; 182:1357-1364.
24. McNeil AC, Shupert WL, Iyasere CA, et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A 2001; 98:13878-13883.
25. Garcia F, Lejeune M, Climent N, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005; 191:1680-1685. Despite the use of low doses of antigen, a therapeutic vaccination using ex-vivo matured dendritic cells loaded with autologous virus tended to decrease the magnitude of viremia after treatment interruption.
26. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359-1365.
27. Lu W, Wu X, Lu Y, et al. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003; 9:27-32.
28. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55:355-372.
29. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006. [Epub ahead of print]
30. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203:2281-2292.
31. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8 + T cells leads to reversible immune dysfunction. Nat Med 2006. [Epub ahead of print] The last three papers identify a pathway that is activated in HIV infection and inhibits the cytolytic function of HIV-reactive CD8 T cells. Interference with this pathway enhances antiviral activities of these cytotoxic T lymphocytes and may point the way to more effective therapeutic vaccine strategies.
32. Kinloch-de Loes S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192:607-617. No antiviral benefit of therapeutic vaccination among individuals who started HAART during acute infection.
33. Emery S, Workman C, Plus RL, et al. Randomized, placebo-controlled, phase 1/11a evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects. Hum Vaccine 2005; 1:232-238. No antiviral benefit of therapeutic vaccination among individuals who started HAART during acute infection.
34. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006; 7:235-239.
35. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000; 14:11-21.
36. Maggiolo F, Ripamonti D, Gregis G, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18:439-446.
37. Lange CG, Valdez H, Medvik K, et al. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102:154-161.
38. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med 1991; 324:1677-1684.
39. Kalams SA, Goulder PJ, Shea AK, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999; 73:6721-6728.
40. Mollet L, Li TS, Samri A, et al. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups. J Immunol 2000; 165:1692-1704.
41. Deeks SG, Martin JN, Sinclair E, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004; 189:312-321.
42. Hunt PW, Deeks SG, Bangsberg DR, et al. The independent effect of drug resistance on T cell activation in HIV infection. AIDS 2006; 20:691-699. Drug-resistant HIV may be less pathogenic if immune activation is a marker of immunopathogenesis.
43. Fernandez-Cruz E, Moreno S, Navarro J, et al. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine 2004; 22:2966-2973.
44. El Sadr W, Neaton J, for the SMART Study Investigators. Episodic CD4-guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO. 5-8 February 2006. Abstract 106 LB.
45. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-1622.
46. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536.
47. Palmer S, Wiegand AP, Maldarelli F, et al. The level of persistent viremia less than 50 copies/ml in patients on suppressive antiretroviral therapy is independent of regimen potency but strongly associated with pretreatment viremia. In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA. 22-25 February 2005. Abstract 163.
48. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
49. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
50. Pierson TC, Zhou Y, Kieffer TL, et al. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 2002; 76:8518-8531.
51. Pantaleo G, Graziosi C, Demarest JF, et al. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev 1994; 140:105-130.
52. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006; 80:6441-6457.